Cerus (CERS) Free Cash Flow Growth (3y) (2013 - 2026)
Cerus (CERS) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.85 Bn | 176.55 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 128.90 Bn | 126.02 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 108.55 Bn | 99.33 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 68.56 Bn | 67.10 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 48.24 Bn | 44.57 Bn | 1.29 Bn | -27.72% |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn | 77.20% |
| 7 | GE HealthCare Technologies | 28.15 Bn | 25.87 Bn | 1.98 Bn | -29.89% |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.75 Bn | 21.63 Bn | 2.07 Bn | -0.27% |
| 10 | Cerus | 604.75 Mn | 524.33 Mn | 27.89 Mn | 31.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.08% |
| Dec 31, 2025 | 53.77% |
| Sep 30, 2025 | 26.74% |
| Jun 30, 2025 | -90.47% |
| Mar 31, 2025 | 64.61% |
| Dec 31, 2024 | 63.17% |
| Sep 30, 2024 | 35.58% |
| Jun 30, 2024 | 26.86% |
| Mar 31, 2024 | 27.01% |
| Dec 31, 2023 | -17.45% |
| Sep 30, 2023 | -34.19% |
| Jun 30, 2023 | -4.07% |
| Mar 31, 2023 | 20.90% |
| Dec 31, 2022 | 29.94% |
| Sep 30, 2022 | 52.24% |
| Jun 30, 2022 | 70.26% |
| Mar 31, 2022 | 5.42% |
| Dec 31, 2021 | 39.50% |
| Sep 30, 2021 | -8.17% |
| Jun 30, 2021 | 1.23% |